Meribank Biotech Co Ltd

As of June 30, 2026, Meribank Biotech Co Ltd carries a market capitalization of 969.36M, placing it among publicly traded companies globally. Its enterprise value stands at 1.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Meribank Biotech Co Ltd has 95.98M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Meribank Biotech Co Ltd maintains a current ratio of 1.70, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Meribank Biotech Co Ltd's stock has declined approximately 53.86% over the past 52 weeks. The 50-day moving average sits at 9.28, while the 200-day moving average is 12.05.

As of June 30, 2026, Meribank Biotech Co Ltd holds 191.32M in cash and equivalents against 1.09B in total debt, resulting in a net debt position of 89.95M. Total book value stands at 1.18B, with working capital of 176.13M providing operational flexibility.

Meribank Biotech Co Ltd's most recent stock split took place on September 22, 2023 with a 96:97 split ratio.